Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
SPRB
Spruce Biosciences, Inc.
NASDAQCM
Biotechnology
United States
$57.93
▲
+0.22 (+0.38%)
CLOSED
—
OPEN
$57.37
HIGH
$58.19
LOW
$56.57
PREV CLOSE
$57.71
VOLUME
103.9K
1.42x avg
BID / ASK
41.04 / 73.10
spr 32.06
MARKET CAP
$166.5M
DAY RANGE
$56.57
$58.19
P/E (TTM)
—
Fwd 7.1
EPS (TTM)
-38.43
DIV YIELD
—
52W HIGH
$240.00
-75.9%
52W LOW
$7.26
+697.9%
BETA
3.36
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$57.93
+0.00
(+0.00%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
SPRB
$57.93
▲
+0.38%
Chart
Valuation
Financials
Peers
News
SPRB · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +543.7% YOY
1-year price chart. Started at 9.00, currently 57.93, up 543.7 percent. Range 7.75 to 182.60 over 252 data points.
2025-09-05
$9.00 → $57.93 (+543.7%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
—
WACC Used
+12.0%
Terminal g
+2.5%
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers. · Comparables dropped — no sector classification for SPRB; a peer set cannot be validated and is not published.
FINANCIALS
多年財務（SEC XBRL）
RISK-OFF
YOY REV -100.0% · 4 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$0.00
-$39.0M
-$33.3M
—
$53.0M
2024-12
$4.9M
-$53.0M
-$56.0M
-$56.0M
$45.2M
2023-12
$10.1M
-$47.9M
-$33.3M
-$33.3M
$103.9M
2022-12
$0.00
-$46.2M
-$41.7M
-$41.7M
$85.6M
NEWS
近期新聞（過去 14 天）
CALM
10 HEADLINES · LAST 14 DAYS
Spruce Biosciences stock gains after analyst backs regulatory progress
InvestorsHub · 2026-08-27
Spruce Biosciences Announces Launch of MPS3BStudy.com
Business Wire · 2026-08-26
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Business Wire · 2026-08-24
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Wire · 2026-08-12
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Business Wire · 2026-08-12
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Business Wire · 2026-08-03
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Business Wire · 2026-07-27
American Express, Biogen upgraded: Wall Street's top analyst calls
The Fly · 2026-07-13